Pharmacoeconomic comparison of dupilumab and lebrikizumab for atopic dermatitis treatment in Italy: cost-per-responder analysis - PubMed
3 hours ago
- #pharmacoeconomics
- #atopic dermatitis
- #cost-effectiveness
- A cost-per-responder model was developed to compare dupilumab and lebrikizumab for moderate-to-severe atopic dermatitis in Italy.
- Two indirect treatment comparisons were conducted: one at 16 weeks using LIBERTY AD CHRONOS and ADhere trials, and another at 52 weeks using LIBERTY AD SOLO-CONTINUE and ADvocate studies.
- At 16 weeks, dupilumab was more effective across endpoints (EASI 75, I-NRS ≥4, IGA 0/1) and showed a lower Number Needed to Treat (NNT) and more favorable cost per responder (delta cost at least -€24,490).
- At 52 weeks, dupilumab remained more favorable in all outcomes, with a difference in cost per responder versus lebrikizumab no less than -€28,649.
- The study concludes that dupilumab provides greater clinical and economic benefits, supporting its preference among healthcare decision-makers.